Selling by month
Oct 2025 to Oct 2026. Each sale is counted once: under a disclosed plan, else to cover taxes, else no plan disclosed.
Disclosed planOne dollar scale for every month; the tallest bar is labeled
Pattern
What the filings show, past 12 months. Nothing here rates or predicts.
- Sold in 3 of the 13 calendar months from Oct 2025 to Oct 2026: Dec 2025, Apr 2026 and Aug 2026.
- Largest single sale: $2.3M (15,000 shares) of Neurocrine Biosciences Inc on Dec 3, 2025. Filing
- Last sale before this period: Oct 4, 2024.
Roles from filings
Every company we track where this person has filed, newest filing first.
| Company | Title | First filing | Latest filing |
|---|---|---|---|
| Travere Therapeutics, Inc. (TVTX) | Director | Oct 10, 2014 | Aug 19, 2026 |
| Neurocrine Biosciences Inc (NBIX) | Director | Dec 15, 2003 | May 29, 2026 |
Also a director at
Recent filings
The last 5 days with transactions, newest first, one line per trade date. Each number links to an SEC filing.
- Aug 18, 2026, Travere Therapeutics, Inc.: sold 5,000 shares for $317K, under a disclosed plan; 5,000 shares acquired by exercising options. 1 filing: 1
- Aug 17, 2026, Travere Therapeutics, Inc.: sold 5,000 shares for $316K, under a disclosed plan; 5,000 shares acquired by exercising options. 1 filing: 1
- May 21, 2026, Neurocrine Biosciences Inc: 1,659 shares vested. 1 filing: 1
- May 19, 2026, Travere Therapeutics, Inc.: 4,000 shares awarded. 1 filing: 1
- Apr 14, 2026, Travere Therapeutics, Inc.: sold 8,000 shares for $329K, under a disclosed plan; 8,000 shares acquired by exercising options. 1 filing: 1
This page shows only what this person reported on SEC ownership filings. See the methodology. Spotted something wrong? Report an error.